As of early 2026, several potent single, dual, and triple incretin receptor agonists are in Phase 2/3 trials for MASH including : Survodutide : A dual glucagon (GCGR)/GLP-1 receptor agonist that has shown significant MASH resolution in Phase 2 trials
Notably, early studies demonstrated that 1,25(OH)D could inhibit the DNA-binding activity of NF-B in human MRC-5 fibroblasts without preventing the nuclear translocation of its p50 or p65 subunits
Benjamin Lynch: Exactly, exactly
Miyashita A, Ito J, Parida IS, Syoji N, Fujii T, Takahashi H, et al
PA requests for non-preferred cytokine and CAM antagonist drugs used to treat JIA and systemic JIA may be submitted on the Portal, by fax, or by mail (but not using the STAT-PA system)
Its how